Medigen Biotechnology (ROCO:3176) Net Issuance of Preferred Stock : NT$0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Medigen Biotechnology's net issuance of preferred for the three months ended in Mar. 2024 was NT$0 Mil. The number is 0, which means that Medigen Biotechnology has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Medigen Biotechnology's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was NT$0 Mil.

Medigen Biotechnology Net Issuance of Preferred Stock Historical Data

The historical data trend for Medigen Biotechnology's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Net Issuance of Preferred Stock Chart

Medigen Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Medigen Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Medigen Biotechnology Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0 Mil.

Medigen Biotechnology Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology (ROCO:3176) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560

Website

https://www.medigen.com.tw

Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines